Eton Pharmaceuticals (ETON) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

ETON Stock Forecast

Eton Pharmaceuticals stock forecast is as follows: an average price target of $13.00 (represents a -23.84% downside from ETON’s last price of $17.07) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

ETON Price Target

The average price target for Eton Pharmaceuticals (ETON) is $13.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $11.00. This represents a potential -23.84% downside from ETON's last price of $17.07.

ETON Analyst Ratings

Buy

According to 7 Wall Street analysts, Eton Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ETON stock is 0 'Strong Buy' (0.00%), 6 'Buy' (85.71%), 1 'Hold' (14.29%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Eton Pharmaceuticals Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 28, 2024	Chase Knickerbocker	Craig-Hallum	$15.00	$8.44	77.73%	-12.13%
Oct 04, 2024	Swayampakula Ramakanth	H.C. Wainwright	$11.00	$6.91	59.19%	-35.56%
May 06, 2024	Chase Knickerbocker	Craig-Hallum	$8.00	$3.71	115.63%	-53.13%
Jul 25, 2022		H.C. Wainwright	$9.00	$2.72	230.88%	-47.28%

The latest Eton Pharmaceuticals stock forecast, released on Oct 28, 2024 by Chase Knickerbocker from Craig-Hallum, set a price target of $15.00, which represents a 77.73% increase from the stock price at the time of the forecast ($8.44), and a -12.13% decrease from ETON last price ($17.07).

Eton Pharmaceuticals Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	3
Avg Price Target	-	-	$11.33
Last Closing Price	$17.07	$17.07	$17.07
Upside/Downside	-100.00%	-100.00%	-33.63%

In the current month, the average price target of Eton Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Eton Pharmaceuticals's last price of $17.07. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Jan 10, 2025	B. Riley		Buy	Initialise
Jan 08, 2025	Craig-Hallum	Buy	Buy	Hold
Oct 28, 2024	Craig-Hallum	Buy	Buy	Hold
Oct 04, 2024	Craig-Hallum	Buy	Buy	Hold
Oct 04, 2024	Deutsche Bank	Buy	Buy	Hold
Oct 04, 2024	Morgan Stanley	Equal-Weight	Equal-Weight	Hold
Oct 04, 2024	Cowen & Co.		Buy	Upgrade
Oct 04, 2024	Macquarie	Buy	Buy	Hold
Oct 04, 2024	H.C. Wainwright	Buy	Buy	Hold
May 06, 2024	Craig-Hallum		Buy	Initialise

Eton Pharmaceuticals's last stock rating was published by B. Riley on Jan 10, 2025. The company Initialise its ETON rating from "null" to "Buy".

Eton Pharmaceuticals Financial Forecast

Eton Pharmaceuticals Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Jun 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$7.03M	$12.00M	$5.30M	$8.50M	$3.22M	$7.36M	$2.18M	$6.09M	$775.00K	$3.07M	$11.90M	$81.00K	$-161.00K	$20.00K	$99.00K	$459.00K	-
Avg Forecast	$27.20M	$25.90M	$24.40M	$22.60M	$25.73M	$21.10M	$19.27M	$13.83M	$10.53M	$9.70M	$8.80M	$7.70M	$7.70M	$6.26M	$6.50M	$4.60M	$9.10M	$3.05M	$7.80M	$7.10M	$7.56M	$3.04M	$3.83M	$12.05M	$1.04M	$1.06M	$294.33K	$1.51M	$670.33K	$777.78K
High Forecast	$30.71M	$29.25M	$27.55M	$25.52M	$29.06M	$23.83M	$21.76M	$15.18M	$10.63M	$9.79M	$9.94M	$8.70M	$8.70M	$7.07M	$7.34M	$5.19M	$9.42M	$3.05M	$7.80M	$7.10M	$7.56M	$3.04M	$3.83M	$12.05M	$1.04M	$1.06M	$294.33K	$1.51M	$670.33K	$933.33K
Low Forecast	$24.26M	$23.10M	$21.76M	$20.16M	$22.95M	$18.82M	$17.18M	$12.48M	$10.43M	$9.60M	$7.85M	$6.87M	$6.87M	$5.58M	$5.80M	$4.10M	$8.78M	$3.05M	$7.80M	$7.10M	$7.56M	$3.04M	$3.83M	$12.05M	$1.04M	$1.06M	$294.33K	$1.51M	$670.33K	$622.22K
# Analysts	1	1	1	1	1	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	7	7	9	9	9	9	13	15
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.12%	1.85%	1.15%	0.93%	1.06%	0.94%	0.31%	0.81%	0.25%	0.80%	0.99%	0.08%	-0.15%	0.07%	0.07%	0.68%	-

Eton Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 1 analysts is $7.70M, with a low forecast of $6.87M, and a high forecast of $8.70M. ETON's average Quarter revenue forecast represents a 9.56% increase compared to the company's last Quarter revenue of $7.03M (Sep 23).

Eton Pharmaceuticals EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Jun 19
# Analysts	1	1	1	1	1	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	7	7	9	9	9	9	13	15
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-548.00K	$3.88M	$-2.32M	$1.06M	$-2.73M	$-169.00K	$-4.91M	$1.45M	$-6.01M	$-1.93M	$5.52M	$-7.53M	$-6.34M	$-4.57M	$-8.89M	$-2.55M	$-3.13M
Avg Forecast	$-12.87M	$-12.25M	$-11.54M	$-10.69M	$-12.18M	$-9.98M	$-9.12M	$-6.55M	$-4.98M	$-4.59M	$-4.16M	$-3.64M	$-3.64M	$-2.96M	$-3.08M	$-2.18M	$-4.31M	$-1.44M	$-3.68M	$-3.07M	$-3.57M	$-1.44M	$-1.81M	$5.52M	$-492.18K	$-500.37K	$-139.03K	$-4.61M	$-316.63K	$-4.38M
High Forecast	$-11.48M	$-10.93M	$-10.30M	$-9.54M	$-10.86M	$-8.90M	$-8.13M	$-5.90M	$-4.94M	$-4.54M	$-3.71M	$-3.25M	$-3.25M	$-2.64M	$-2.74M	$-1.94M	$-4.16M	$-1.44M	$-3.68M	$-2.45M	$-3.57M	$-1.44M	$-1.81M	$6.62M	$-492.18K	$-500.37K	$-139.03K	$-3.69M	$-316.63K	$-3.50M
Low Forecast	$-14.53M	$-13.84M	$-13.04M	$-12.08M	$-13.75M	$-11.27M	$-10.29M	$-7.18M	$-5.03M	$-4.63M	$-4.70M	$-4.11M	$-4.11M	$-3.34M	$-3.47M	$-2.46M	$-4.46M	$-1.44M	$-3.68M	$-3.68M	$-3.57M	$-1.44M	$-1.81M	$4.41M	$-492.18K	$-500.37K	$-139.03K	$-5.53M	$-316.63K	$-5.25M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.19%	-1.26%	1.07%	-0.25%	1.89%	0.05%	1.60%	-0.41%	4.18%	1.07%	1.00%	15.29%	12.67%	32.84%	1.93%	8.05%	0.71%

1 analysts predict ETON's average Quarter EBITDA for Sep 23 to be $-2.96M, with a high of $-2.64M and a low of $-3.34M. This is -176.27% lower than Eton Pharmaceuticals's previous annual EBITDA (Jun 23) of $3.88M.

Eton Pharmaceuticals Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Jun 19
# Analysts	1	1	1	1	1	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	7	7	9	9	9	9	13	15
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-579.00K	$4.56M	$-2.91M	$912.00K	$-3.19M	$-1.78M	$-5.57M	$764.00K	$-6.09M	$-2.02M	$5.12M	$-7.69M	$-6.50M	$-4.73M	$-9.05M	$-2.70M	$-3.25M
Avg Forecast	$9.82M	$8.76M	$7.70M	$6.90M	$6.46M	$4.43M	$2.65M	$884.99K	$-88.49K	$-265.50K	$-1.86M	$-1.86M	$-1.06M	$-2.65M	$-2.39M	$-3.72M	$265.50K	$-3.87M	$773.34K	$-3.33M	$1.29M	$-3.48M	$-3.61M	$5.12M	$-6.83M	$-6.53M	$-6.70M	$-4.69M	$-6.79M	$-4.41M
High Forecast	$11.47M	$10.23M	$8.99M	$8.06M	$7.55M	$5.17M	$3.10M	$1.03M	$44.24K	$-228.18K	$-1.60M	$-1.60M	$-912.72K	$-2.28M	$-2.05M	$-3.19M	$277.56K	$-3.87M	$773.34K	$-2.67M	$1.29M	$-3.48M	$-3.61M	$6.14M	$-6.83M	$-6.53M	$-6.70M	$-3.75M	$-6.79M	$-3.53M
Low Forecast	$8.44M	$7.53M	$6.62M	$5.93M	$5.55M	$3.80M	$2.28M	$663.74K	$-176.98K	$-310.10K	$-2.17M	$-2.17M	$-1.24M	$-3.10M	$-2.79M	$-4.34M	$253.44K	$-3.87M	$773.34K	$-4.00M	$1.29M	$-3.48M	$-3.61M	$4.09M	$-6.83M	$-6.53M	$-6.70M	$-5.63M	$-6.79M	$-5.29M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.22%	-1.91%	0.78%	3.44%	0.83%	-2.30%	1.67%	0.59%	1.75%	0.56%	1.00%	1.13%	1.00%	0.71%	1.93%	0.40%	0.74%

Eton Pharmaceuticals's average Quarter net income forecast for Sep 23 is $-2.65M, with a range of $-3.10M to $-2.28M. ETON's average Quarter net income forecast represents a -158.24% decrease compared to the company's last Quarter net income of $4.56M (Jun 23).

Eton Pharmaceuticals SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Jun 19
# Analysts	1	1	1	1	1	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	7	7	9	9	9	9	13	15
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$4.34M	$4.67M	$5.34M	$4.35M	$4.17M	$5.26M	$4.93M	$3.82M	$3.33M	$3.27M	$4.06M	$3.80M	$3.43M	$2.92M	$2.61M	$2.43M	$1.91M
Avg Forecast	$1.83B	$1.75B	$1.65B	$1.52B	$1.74B	$1.42B	$1.30B	$932.89M	$710.08M	$653.84M	$593.45M	$519.27M	$519.27M	$422.09M	$438.35M	$310.21M	$613.69M	$205.62M	$526.02M	$3.08M	$510.03M	$205.08M	$258.42M	$4.06M	$70.27M	$71.44M	$19.85M	$1.35M	$45.21M	$52.45M
High Forecast	$2.07B	$1.97B	$1.86B	$1.72B	$1.96B	$1.61B	$1.47B	$1.02B	$716.73M	$660.44M	$670.14M	$586.38M	$586.38M	$476.64M	$494.99M	$350.30M	$635.13M	$205.62M	$526.02M	$3.70M	$510.03M	$205.08M	$258.42M	$4.87M	$70.27M	$71.44M	$19.85M	$1.62M	$45.21M	$62.94M
Low Forecast	$1.64B	$1.56B	$1.47B	$1.36B	$1.55B	$1.27B	$1.16B	$841.62M	$703.43M	$647.25M	$529.29M	$463.12M	$463.12M	$376.45M	$390.95M	$276.67M	$592.24M	$205.62M	$526.02M	$2.46M	$510.03M	$205.08M	$258.42M	$3.25M	$70.27M	$71.44M	$19.85M	$1.08M	$45.21M	$41.96M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.01%	0.01%	0.02%	0.01%	0.02%	0.01%	1.60%	0.01%	0.02%	0.01%	1.00%	0.05%	0.05%	0.15%	1.93%	0.05%	0.04%

Eton Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $519.27M, based on 1 Wall Street analysts, with a range of $463.12M to $586.38M. The forecast indicates a 11875.84% rise compared to ETON last annual SG&A of $4.34M (Sep 23).

Eton Pharmaceuticals EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Jun 19
# Analysts	1	1	1	1	1	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	7	7	9	9	9	9	13	15
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.02	$0.18	$-0.11	$0.04	$-0.13	$-0.07	$-0.22	$0.03	$-0.24	$-0.08	$0.21	$-0.32	$-0.31	$-0.23	$-0.50	$-0.15	$-0.18
Avg Forecast	$0.37	$0.33	$0.29	$0.26	$0.24	$0.17	$0.10	$0.03	$-0.00	$-0.01	$-0.07	$-0.07	$-0.04	$-0.10	$-0.09	$-0.14	$0.01	$-0.15	$0.03	$-0.08	$0.05	$-0.14	$-0.14	$0.19	$-0.27	$-0.25	$-0.26	$-0.22	$-0.26	$-0.28
High Forecast	$0.43	$0.39	$0.34	$0.30	$0.28	$0.19	$0.12	$0.04	-	$-0.01	$-0.06	$-0.06	$-0.03	$-0.09	$-0.08	$-0.12	$0.01	$-0.15	$0.03	$-0.08	$0.05	$-0.14	$-0.14	$0.19	$-0.27	$-0.25	$-0.26	$-0.22	$-0.26	$-0.28
Low Forecast	$0.32	$0.28	$0.25	$0.22	$0.21	$0.14	$0.09	$0.02	$-0.01	$-0.01	$-0.08	$-0.08	$-0.05	$-0.12	$-0.11	$-0.16	$0.01	$-0.15	$0.03	$-0.08	$0.05	$-0.14	$-0.14	$0.19	$-0.27	$-0.25	$-0.26	$-0.22	$-0.26	$-0.28
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.22%	-2.00%	0.79%	4.00%	0.87%	-2.36%	2.75%	0.60%	1.78%	0.57%	1.11%	1.21%	1.22%	0.88%	2.24%	0.57%	0.65%

According to 1 Wall Street analysts, Eton Pharmaceuticals's projected average Quarter EPS for Sep 23 is $-0.10, with a low estimate of $-0.12 and a high estimate of $-0.09. This represents a -155.56% decrease compared to ETON previous annual EPS of $0.18 (Jun 23).

Eton Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
PASG	Passage Bio	$0.58	$6.00	934.48%	Buy
BDTX	Black Diamond Therapeutics	$2.44	$20.00	719.67%	Buy
ABOS	Acumen Pharmaceuticals	$1.57	$7.00	345.86%	Buy
GOSS	Gossamer Bio	$0.92	$3.75	307.61%	Buy
CELC	Celcuity	$11.46	$39.00	240.31%	Buy
NUVB	Nuvation Bio	$2.42	$7.00	189.26%	Buy
LYRA	Lyra Therapeutics	$0.18	$0.50	177.78%	Hold
ALEC	Alector	$1.64	$4.00	143.90%	Buy
ALDX	Aldeyra Therapeutics	$5.18	$12.00	131.66%	Buy
ELVN	Enliven Therapeutics	$20.86	$39.50	89.36%	Buy
REPL	Replimune Group	$14.07	$23.00	63.47%	Buy
CNTB	Connect Biopharma	$0.97	$1.50	54.64%	Buy
TARS	Tarsus Pharmaceuticals	$53.07	$67.00	26.25%	Buy
TVTX	Travere Therapeutics	$20.45	$21.75	6.36%	Buy
KRON	Kronos Bio	$1.02	$1.00	-1.96%	Buy
ETON	Eton Pharmaceuticals	$17.07	$13.00	-23.84%	Buy

ETON Forecast FAQ

Is Eton Pharmaceuticals a good buy?

Yes, according to 7 Wall Street analysts, Eton Pharmaceuticals (ETON) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 85.71% of ETON's total ratings.

What is ETON's price target?

Eton Pharmaceuticals (ETON) average price target is $13 with a range of $11 to $15, implying a -23.84% from its last price of $17.07. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Eton Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for ETON stock, the company can go down by -23.84% (from the last price of $17.07 to the average price target of $13), down by -12.13% based on the highest stock price target, and down by -35.56% based on the lowest stock price target.

Can Eton Pharmaceuticals stock reach $30?

ETON's average twelve months analyst stock price target of $13 does not support the claim that Eton Pharmaceuticals can reach $30 in the near future.

What are Eton Pharmaceuticals's analysts' financial forecasts?

Eton Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $79.93M (high $89.82M, low $71.43M), average EBITDA is $-37.82M (high $-33.798M, low $-42.498M), average net income is $14.43M (high $16.85M, low $12.3M), average SG&A $5.39B (high $6.06B, low $4.82B), and average EPS is $0.543 (high $0.635, low $0.463). ETON's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $100.1M (high $113.04M, low $89.28M), average EBITDA is $-47.362M (high $-42.241M, low $-53.483M), average net income is $33.19M (high $38.76M, low $28.52M), average SG&A $6.75B (high $7.62B, low $6.02B), and average EPS is $1.25 (high $1.46, low $1.07).

Did the ETON's actual financial results beat the analysts' financial forecasts?

Based on Eton Pharmaceuticals's last annual report (Dec 2022), the company's revenue was $21.25M, which missed the average analysts forecast of $27.05M by -21.44%. Apple's EBITDA was $-6.486M, missing the average prediction of $-12.496M by -48.10%. The company's net income was $-9.782M, beating the average estimation of $-6.159M by 58.82%. Apple's SG&A was $18.58M, missing the average forecast of $1.35B by -98.62%. Lastly, the company's EPS was $-0.39, beating the average prediction of $-0.19 by 105.26%. In terms of the last quarterly report (Sep 2023), Eton Pharmaceuticals's revenue was $7.03M, beating the average analysts' forecast of $6.26M by 12.29%. The company's EBITDA was $-548K, missing the average prediction of $-2.961M by -81.50%. Eton Pharmaceuticals's net income was $-579K, missing the average estimation of $-2.655M by -78.19%. The company's SG&A was $4.34M, missing the average forecast of $422.09M by -98.97%. Lastly, the company's EPS was $-0.0225, missing the average prediction of $-0.1 by -77.50%